A proof-of-concept, single-arm, phase II clinical trial, led by investigators from the Mass General Cancer Center, reported a long-lasting response among patients who responded to the combined treatment and reveals how a targeted therapy may cooperate with an immunotherapy for better results.
A study, led by Randy Vince Jr. and Daniel Spratt, demonstrated the link between cancer outcomes and social determinants of health, as opposed to only race.
Phase I results from the phase I/II study of Rezlidhia (olutasidenib), an investigational, oral, small molecule inhibitor of mutant isocitrate dehydrogenase-1, suggests that Rezlidhia, with or without azacitidine, was well-tolerated and was associated with improvements in clinical efficacy endpoints in patients with mIDH1 acute myeloid leukemia.
Patients who have intrahepatic cholangiocarcinoma caused by specific FGFR2 gene alterations may soon have a better treatment option that more successfully targets that mutation.
A drug that recently received accelerated approval from FDA to treat a form of non-small cell lung cancer caused by a unique genetic mutation also appears to be effective against advanced pancreatic cancer caused by the same uncommon mutation.
An analysis led by a researcher at UT Southwestern Medical Center, which looked at costs for patients with Hepatocellular carcinoma in the first year after diagnosis, found that median Medicare payments exceeded $65,000 and out-of-pocket costs were more than $10,000—significantly more than costs for patients with cirrhosis alone.
Scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, collaborating with international researchers, have developed an AI algorithm that performs advanced computational analysis to identify potential therapeutic targets for glioblastoma multiforme and other cancers.
Yale Cancer Center scientists have developed a technology that enables massively parallel DNA substitutions (known as “knock-ins”) into human cells by taking advantage of messenger RNA, a platform now well-known from its use as the COVID vaccine vehicle.
In a study published in Cell Reports Medicine, a team of scientists at Baylor College of Medicine focused on the molecular pathways metastatic cancer cells use and identified four cancer subtypes according to the main genes expressed. The findings unveiled potential vulnerabilities of each subtype that have relevant implications for therapy.
Researchers at Baylor College of Medicine, the University of Michigan, and collaborating institutions working with animal models of graft-versus-host disease reported in Immunity that alterations in the gut microbiome are connected to an increase in the oxygen levels in the intestine that follows immune-mediated intestinal damage. Pharmacologically reducing intestinal oxygen levels alleviated the microbial imbalance and reduced the severity of the intestinal disease.
